reports
Fulcrum Therapeutics Announces Recent Business Highlights and Financia...
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2024 ― Entered into a collaboration and ex-U.S. license agreement with Sanofi for the development and commercialization of losmapimod ― ― On track to report topline data for Phase 3 REACH trial of losmapimod in facioscapulohumeral muscular dystrophy (FSHD) in the fourth quarter of 2024 ― ― Industry veteran, Patrick Horn M.D., Ph.D., appointed as chief medical officer ― ― Conference call and webcast scheduled for 8:00 a.m. ET today ― CAMBRIDGE, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Fulcr...
Fulcrum Therapeutics Enters into a Collaboration and License Agreement...
Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy ― Sanofi receives exclusive rights to commercialize losmapimod in all territories outside the U.S.; Fulcrum retains full U.S. commercialization rights ― ― Fulcrum will receive an upfront payment of $80.0 million, and is eligible to receive $975.0 million in potential milestones, plus royalties on ex-U.S. product sales; parties will share future global development costs 50:50 ― ― Conference call and webc...
Fulcrum Therapeutics to Participate in Upcoming May Conferences
Fulcrum Therapeutics to Participate in Upcoming May Conferences CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that management will participate in the following conferences: RBC Capital Market Global Healthcare ConferenceWednesday May 15 at 4:05 p.m. ET. (Fireside Chat)Link to register for the Fireside Chat can be found H.C. Wainwright 2nd Annual BioConnec...
Fulcrum Therapeutics Announces Publication of Results from Phase 2b Cl...
Fulcrum Therapeutics Announces Publication of Results from Phase 2b Clinical Trial of Losmapimod in Facioscapulohumeral muscular dystrophy (ReDUX4) in The Lancet Neurology ― Phase 2b ReDUX4 clinical trial indicates improvements in functional, structural, and patient-reported outcomes; findings informed the design and choice of efficacy endpoints in the ongoing Phase 3 clinical trial― ― Topline data for the Phase 3 REACH clinical trial of losmapimod in FSHD expected during 4Q’24― CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-sta...
Fulcrum Therapeutics to Host First Quarter 2024 Financial Results Conf...
Fulcrum Therapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Monday, May 13, 2024, at 8:00 a.m. ET CAMBRIDGE, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that its first quarter 2024 financial results will be released on Monday, May 13, 2024 before the U.S. financial markets open. Management will host a conference call and webcast a...
Appian Announces First Quarter 2024 Financial Results
Appian Announces First Quarter 2024 Financial Results First quarter cloud subscription revenue increased 24% year-over-year to $86.6 million MCLEAN, Va., May 02, 2024 (GLOBE NEWSWIRE) -- Appian (Nasdaq: APPN) today announced financial results for the first quarter ended March 31, 2024. “Appian continues to push technological boundaries in our industry, from AI-backed services to process mining. Organizations globally are recognizing the power and simplicity of the Appian Platform,” said Matt Calkins, CEO & Founder. First Quarter 2024 Financial Highlights: Revenue: Cloud subscription ...
Atlassian Announces Third Quarter Fiscal Year 2024 Results and CEO Tra...
Team Anywhere/SAN FRANCISCO--(BUSINESS WIRE)-- Atlassian Corporation (NASDAQ: TEAM), a leading provider of team collaboration and productivity software, today announced financial results for its third quarter ended March 31, 2024. Atlassian also announced co-founder Scott Farquhar will step down as co-CEO effective August 31, 2024, with co-founder Mike Cannon Brookes continuing to lead Atlassian as CEO. A shareholder letter was posted on Atlassian’s Work Life blog at and in the Investor Relations section of Atlassian’s website at . Third Quarter Fiscal Year 2024 Earnings Results “It’s bee...
Appian To Announce First Quarter 2024 Financial Results on May 2
Appian To Announce First Quarter 2024 Financial Results on May 2 MCLEAN, Va., April 24, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: APPN) today announced that it will release financial results for the first quarter ended March 31, 2024, before the U.S. financial markets open on Thursday, May 2, 2024. The company will host a conference call and live webcast to review its financial results and business outlook. Conference Call Details The conference call will begin at 8:30 a.m. Eastern Time. To access the call, please use this . Once registered, participants can dial in the same way they alway...
Appian to Host Investor Day at Appian World on April 16
Appian to Host Investor Day at Appian World on April 16 MCLEAN, Va., April 08, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: APPN) announced today that it will host its Investor Day on Tuesday, April 16, 2024 at 1:30 p.m. Eastern Time. The event will take place during Appian World, the company's annual customer conference. A live webcast of the event will be available under the "News and Events " section of the Company's investor relations website at . About AppianAppian is a software company that automates business processes. The Appian AI Platform includes everything you need to design, automate...
Atlassian Announces Dates for Third Quarter of Fiscal Year 2024 Financ...
Team Anywhere/SAN FRANCISCO--(BUSINESS WIRE)-- Atlassian Corporation (NASDAQ: TEAM), a leading provider of team collaboration and productivity software, today announced that it will release financial results for its third quarter of fiscal year 2024 ended March 31, 2024 after market close on Thursday, April 25, 2024. Atlassian will host a webcast and conference call to discuss the financial results at 2:00 P.M. Pacific Time. In conjunction with its earnings press release, Atlassian will post a shareholder letter to the Investor Relations section of its website at . Webcast Details When: T...
Fulcrum Therapeutics to Participate at the Cantor Virtual Muscular Dys...
Fulcrum Therapeutics to Participate at the Cantor Virtual Muscular Dystrophy Symposium CAMBRIDGE, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that management will participate in a fireside chat at the Cantor Virtual Muscular Dystrophy Symposium, being held on Tuesday, April 2, 2024 at 10:40 a.m. ET. The webcast of the presentation will be accessible and by visi...
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Ru...
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass., March 22, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to Patrick Horn, M.D., Ph.D., the company’s newly appointed chief medical officer. Fulcrum granted stock options to purchase shares of the company’s common stock pursuant to the company’s 202...
Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medic...
Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officer ―Industry veteran with late-stage clinical development, medical affairs, and regulatory experience; well-positioned to advance losmapimod towards a potential regulatory submission and approval ― ― Interim Chief Medical Officer, Iain Fraser, MBChB, DPhil, will continue to serve on Fulcrum’s executive leadership team as senior vice president (SVP) of early development ― CAMBRIDGE, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (Nasdaq: FULC), a clinical-stage biopharmaceutical...
Greenwich LifeSciences Extends Lock-up of Directors and Officers to Ju...
Greenwich LifeSciences Extends Lock-up of Directors and Officers to June 30, 2025 STAFFORD, Texas, March 13, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that its Board of Directors has extended the lock-up of the shares owned by the Company's directors, officers, and existing pre-IPO investors to June 30, 2025 which is approximately 57 months from date ...
Greenwich LifeSciences Partners with GEICAM in Spain & Conducts First ...
Greenwich LifeSciences Partners with GEICAM in Spain & Conducts First Site Initiation Visits in Europe STAFFORD, Texas, March 12, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the initiation of the first clinical sites in Europe in collaboration with GEICAM in Spain. The Company has partnered with GEICAM, the largest academic breast cancer research n...
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Ru...
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass., March 08, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to two new employees. Fulcrum granted stock options to purchase shares of the company’s common stock pursuant to the company’s 2022 Inducement Stock Incentive Plan, as amended, or the plan, a...
- Jonathan Moreland
Fulcrum Therapeutics to Participate at the Leerink Partners Global Bio...
Fulcrum Therapeutics to Participate at the Leerink Partners Global Biopharma Conference CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that management will present a corporate overview at the Leerink Partners Global Biopharma Conference, being held in Miami, FL on Wednesday, March 13, 2024 at 9:20 a.m. ET. Management will also participate in one-on-one inve...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.